ABMD - Abiomed topline up 5% beats FQ3 consensus

Abiomed (ABMD) FQ3:Revenue: $231.7M (+4.6%).Worldwide Impella® heart pump revenue: $220.8M (+4%).Operating income: $71.4M (+2%).Gross margin: 82.3% vs 82% last year.Operating cash flow: $79.1MFQ4 revenue outlook: To be in the range of $225M to $235MOn January 7, the company announced it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending.As of December 31, 2020, the company had $787.8M of cash and marketable securities and no debt.Previously (Jan. 28): Abiomed EPS beats by $0.07, beats on revenue

For further details see:

Abiomed topline up 5%, beats FQ3 consensus